YDYatin Dholakia

Yatin Dholakia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yatin Dholakia has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diet and nutrition status of adult multidrug-resistant tuberculosis cases, household controls, and community controls in Mumbai, India

    by Laxmi Govekar, Sabri Bromage, Uttara Partap, Anupam Shukla, Prachi Dev, Yatin Dholakia, Wafaie W. Fawzi, Nerges Mistry

    India accounts for the largest national proportion of global multi-drug resistant (MDR-TB) cases and TB mortality. However, evidence on the role of diet and nutrition in MDR-TB infection remains limited. This study aimed to multifacetedly evaluate and compare diet and nutrition status of MDR-TB cases and controls in high TB-burden slum areas of Mumbai. We recruited 352 pulmonary MDR-TB cases receiving domiciliary treatment, household controls, and age-, sex-, and area-matched community controls 18–60 years of age. Participants were assessed for habitual food and nutrient intake using a validated semi-quantitative food-frequency questionnaire, other food consumption-related habits, diet quality metrics, anthropometry, biochemical measurements, and diet-related non-communicable diseases. Measures of diet and nutrition status were compared within and between study arms using hypothesis tests and multiple regression. The prevalence of dietary adequacy was < 50% for 18 of 24 assessed nutrients among cases and 12/24 nutrients among controls. Compared to both household and community controls, cases had significantly (p < 0.05) higher prevalence of underweight (66% vs. 23% and 15%, respectively), anemia (22% vs. 9% and 10%), and diabetes (18% vs. 4% and 5%); lower consumption of major healthy food groups including non-tuberous vegetables, deep orange vegetables, legumes, whole grains, and nuts and seeds; lower Global Diet Quality Score (GDQS); and higher prevalence of nutrient inadequacies including protein, thiamine, folate, and vitamins A, C, and E. Women had significantly poorer adequacy of most nutrients than men in all three study arms, and intake of most nutrients declined with asset index and age in models adjusted for age, sex, study arm, and asset index. Results indicate an urgent need to improve diet and nutrition in Mumbai slum dwellers – particularly among the MDR-TB-infected population, women, the elderly, and the poorest households – and highlights the potentially key role of nutrition interventions in reducing MDR-TB burden in urban India.


  • Open Access

    Impact of COVID-19 vaccine doses and viral waves on inflammatory and immunological responses to COVID-19 infections in India

    by Kamal Kant Sharma, Uttara Partap, Yogesh Marathe, Sanaa Shaikh, Pradeep D’costa, Gaurav Gupta, Molin Wang, Wafaie W Fawzi, Kevin C Kain, Nerges Mistry, et al.

    Background: Investigation of the effect of SARS-CoV-2 variants and COVID-19 vaccination on inflammatory and immune response to SARS-CoV-2 infection is limited in South Asia. Objectives: We aimed to examine the impact of COVID-19 vaccination and waves of COVID- 19 on inflammatory and immunological biomarkers among COVID-19 patients in India. Methods: This cross-sectional analysis used baseline data from a randomized controlled trial of vitamin D and zinc during COVID-19 infection in India (N=181). Blood samples and data regarding vaccination doses were collected. The second (Delta) or third (Omicron) wave was determined by date of enrolment. Mixed effects linear regression with robust standard errors was used to examine associations between COVID-19 vaccination dose or wave at enrolment and C-Reactive Protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, interleukin-6 (IL-6), angiopoietin-2 (Ang-2), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG) and immunoglobulin M (IgM). Results: Compared to no vaccination, full vaccination was associated with lower LDH ( P< 0.001), D-dimer ( P= 0.521) and Ang-2 ( P= 0.046), and higher IgG levels ( P< 0.001). Partial vaccination was associated with lower IL-6 ( P= 0.040) and higher IgG ( P< 0.001). Enrolment during the third wave was associated with lower IL-6 ( P< 0.001), CRP ( P= 0.056), IgM ( P= 0.013), and IgG ( P< 0.001), but higher D-dimer levels ( P< 0.001). Conclusions: COVID-19 vaccination status and SARS-CoV-2 variant influence the inflammatory and immunologic response during SARS-CoV-2 infection, contributing to the severity of clinical presentation.

  • Open Access

    Randomised trial to determine the effect of vitamin D and zinc supplementation for improving treatment outcomes among patients with COVID-19 in India: trial protocol

    by Kamal Kant Sharma, Uttara Partap, Nerges Mistry, Yogesh Marathe, Molin Wang, Sanaa Shaikh, Pradeep D'COsta, Gaurav Gupta, Sabri Bromage, Elena C Hemler, et al.

    Introduction Presently, there are few population-level strategies to address SARS-CoV-2 infection except preventive measures such as vaccination. Micronutrient deficiency, particularly vitamin D and zinc deficiency, has been associated with dysregulated host responses, and may play an important role in COVID-19. Methods and analysis We have designed a 2×2 factorial, randomised, double-blind, multi-centre placebo-controlled trial to evaluate the effect of vitamin D and zinc on COVID-19 outcomes in Maharashtra, India. COVID-19 positive individuals are recruited from hospitals in Mumbai and Pune. Participants are provided (1) vitamin D3 bolus (180 000 IU) maintained by daily dose of 2000 IU and/or (2) zinc gluconate (40 mg daily), versus placebo for 8 weeks. Participants undergo a detailed assessment at baseline and at 8 weeks, and are monitored daily in hospital or every 3 days after leaving the hospital to assess symptoms and other clinical measures. A final follow-up telephone call occurs 12 weeks post-enrolment to assess long-term outcomes. The primary outcome of the study is to time to recovery, defined as time to resolution of all of fever, cough and shortness of breath. Secondary outcomes include: duration of hospital stay, all-cause mortality, necessity of assisted ventilation, change in blood biomarker levels and individual symptoms duration. Participant recruitment commenced on April 2021. Ethics and dissemination Ethical approval was obtained from institutional ethical committees of all participating institutions. The study findings will be presented in peer-reviewed medical journals. Trial registration numbers NCT04641195, CTRI/2021/04/032593, HMSC (GOI)-2021-0060.


  • Open Access

    Effect of public-private interface agency in Patna and Mumbai, India: Does it alter durations and delays in care seeking for drug-sensitive pulmonary tuberculosis?

    by Sanchi Shah, Shimoni Shah, Sheela Rangan, Sonukumar Rai, Eunice Lobo, Swaran Kamble, Yatin Dholakia, Nerges Mistry

    Background: Public–private interface agency (PPIA) intervention models in Patna (E. India) and Mumbai (W. India) for pulmonary drug-sensitive (DS) tuberculosis (TB) patients were evaluated over 2 years after maturity to examine effect on reduction of patient pathways and retention. The models engaged private providers, diagnostic facilities and pharmacies into an effective network providing free diagnostic tests and treatment. Methods: A population-based retrospective study was undertaken to assess effectiveness of the PPIA model in care pathways of 64 (Patna) and 86 (Mumbai) patients through in-depth interviews conducted within 6 months of initiation treatments to identify types and facilities accessed, duration to diagnosis and treatment. Median durations based on facilities accessed were statistically analysed. Comparisons were made with baseline values and endline pathways of patients accessing PPIA engaged/non-engaged facilities in private and public sectors. Results: Compared to non-engaged facilities, persons accessing engaged facilities at first point-of-care had shorter pathways (Mumbai: 32 vs 43 days), (Patna: 15 vs 40 days). Duration for first care-seeking was considerably shorter for patients accessing PPIA in Patna and for both engaged and non-engaged private facilities in Mumbai (4 days). Whilst PPIA engaged facilities diagnosed more cases than others, the RNTCP in Mumbai provided diagnosis early. There was good retention of patients by PPIA-engaged (1st) facilities (90% post-diagnosis in Patna) but this was affected by the hub-spoke referral system in Mumbai (13%). Second diagnosis is a common feature in Mumbai. The spoke-hub model in Mumbai contributed considerably to treatment delay; PPIA-engaged providers were better at retaining patients post treatment initiation 11/25 (44%). Conclusion: PPIA-engaged facilities, accessed at onset, result in marked reduction in pathway durations. Such initiatives should engage a critical mass of competent providers, proximal investigation facilities with enhanced disease awareness and literacy efforts amongst communities. Patient movement should be minimized for early treatment and retention.


  • Open Access

    Such a long journey: What health seeking pathways of patients with drug resistant tuberculosis in Mumbai tell us

    by Aruna Bhattacharya Chakravarty, Sheela Rangan, Yatin Dholakia, Sonu Rai, Swaran Kamble, Tejaswi Raste, Sanchi Shah, Shimoni Shah, Nerges Mistry

    The Indian Tuberculosis (TB) Programme currently faces the dual challenges of tackling increasing numbers of drug resistant (DR) TB cases and regulating practices of a pluralistic private sector catering to TB patients. A study of health seeking behaviour of DR-TB patients in such a situation, offers an opportunity to understand the problems patients face while interacting with health systems. Forty-six DR-TB patients drawn from 15 high TB burden wards in Mumbai were interviewed using an open ended interview tool. Interviews were audio recorded and transcribed. Pathway schematics developed from analysis of patient records, were linked to transcripts. Open coding was used to analyse these units and themes were derived after collating the codes. The paper presents themes interwoven with narratives in the discussions. These include awareness-action gap among patients, role of neighbourhood providers, responsiveness of health systems, the not-such a ‘merry go round’ that patients go/are made to go on while seeking care, costs of diagnostics and treatment, and how DR-TB is viewed as the ‘big TB’. The recommendations are based on a preventative ethos which is sustainable, compared to interventions with top-down approaches, which get piloted, but fail to sustain impact when scaled up.


  • Open Access

    Pathway to care for drug resistant tuberculosis cases identified during a retrospective study conducted in high TB burden wards in Mumbai

    by Eunice Lobo, Shimoni Shah, Sheela Rangan, Yatin Dholakia, Nerges Mistry

    Background: Mumbai is witnessing a rising incidence of all forms of drug resistant tuberculosis (DR-TB). Methods: A population-based, retrospective study was conducted between April and July 2014, in 15 high TB burden wards in Mumbai, to capture the patient pathways to TB care. A total of 23 DR-TB patients were identified and their pathways to access DR-TB care were recorded using semi-structured interviews. Results: The total DR-TB pathway time of new patients (who did not report any past episode of TB) (180 days; IQR 123,346) was found to be more than twice that of retreatment patients (who reported a past episode of TB) (69 days; IQR 42,128). Conclusions: The unacceptable delay for diagnosis and treatment of DR-TB in Mumbai advocates for consistent implementation of early screening of patients using rapid gene-based technologies.